Trade VIRBAC - VIRP CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 1.68
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.01802 %(-€3.60)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.01802%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.00421 %(-€0.84)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.00421%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: France
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.01802 %
  (-€3.60)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.00421 %
  (-€0.84)

Key Stats

• Prev. Close: 335.16
• Open: 334.66
• 1-Year Change: 8.41%
• Day's Range: 334.66 - 337.66

Trade VIRBAC - VIRP

About Virbac SA

Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.

Financial summary

BRIEF: For the six months ended 30 June 2021, Virbac SA revenues increased 11% to EUR529.4M. Net income applicable to common stockholders increased 54% to EUR72.7M. Revenues reflect Food Producting Animals segment increase of 14% to EUR215.9M, Companion Animals segment increase of 6% to EUR300.6M, Europe (excluding France) segment increase of 18% to EUR142.3M, Asia segment increase of 24% to EUR90.9M.